4649-27-8

Usage

Uses

Used in Organic Synthesis:
1,3-Dioxo-2-phenylisoindoline-5-carboxylic acid is used as a building block for the synthesis of various organic molecules. Its unique structure allows it to be a valuable component in creating complex organic compounds for a range of applications.
Used in Drug Discovery:
Due to its potential biological activity, 1,3-Dioxo-2-phenylisoindoline-5-carboxylic acid is used as a starting point in drug discovery. It may contribute to the development of new pharmaceuticals, although further research is necessary to fully understand its properties and potential uses in this field.
Further research is needed to explore the full potential of 1,3-Dioxo-2-phenylisoindoline-5-carboxylic acid in both organic synthesis and drug discovery, as its unique structure and properties could lead to significant advancements in these areas.

InChI:InChI=1/C15H9NO4/c17-13-11-7-6-9(15(19)20)8-12(11)14(18)16(13)10-4-2-1-3-5-10/h1-8H,(H,19,20)

Upstream product

• 538-51-2 benzylidene phenylamine 
• 552-30-7 trimellitic Anhydride 
• 62-53-3 aniline 

Downstream Products

• 868622-64-4 1,3-dioxo-2-phenyl-2,3-dihydro-1H-isoindole-5-carboxylic acid tert-butoxy-amide 
• 24910-57-4 4-(p-carboxybenzoyl)phthalic acid 
• 24910-58-5 4-(p-carboxybenzoyl)phthalic anhydride 
• 64972-07-2 methyl 2,3-dihydro-1,3-dioxo-2-phenyl-1H-isoindole-5-carboxylic acid 

Relevant academic research and scientific papers

NEW PLASMA LIPID LOWERING AGENTS

The present invention relates to new plasma lipid lowering compounds and pharmacological compositions,and their use in the prophylaxis, prevention and treatment of hyperlipidemia, including hypertriglyceridemia, hyperlipoproteinemia, and hypercholesterolemia, as well as hyperlipidemia-related diseases.

Synthesis and characterization of poly(amideimide)s from 4-(p-carboxyphenoxy)phthalic anhydride and 4-(p-carboxybenzoyl)phthalic anhydride

A series of poly(amideimide)s were prepared by the reaction of two new anhydride acidchloride monomers with aromatic diamines. 4-(p-Carboxyphenoxy) phthalic anhydride was synthesized by nucleophilic displacement reaction of N-methyl-4-nitrophthalimide with p-hydroxybenzoic acid, followed by hydrolysis. The tricarboxylic acid was converted to the corresponding anhydride acidchloride. 4-(p-Carboxybenzoyl)phthalic anhydride was synthesized by Friedel-Craft's acylation of toluene with N-phenylphthalimide-4- carbonylchloride, which was then converted to anhydride acidchloride of 4-(p-carboxybenzoyl)phthalic acid. The monomers were characterized by IR and NMR. Several PAI were prepared by the reaction of these anhydride acidchloride monomers with aromatic diamines. The inherent viscosities of the polymers were in the range of 0.42-0.58 dL/g. All polymers were soluble in polar aprotic solvents. The polymers showed good thermal stability and Tg values were in the range of 226-269 C. X-Ray diffractograms of polymers indicate amorphous nature of these polymers.

An expedient method to the synthesis of N-substituted 1H-isoindole-1,3(2H)- diones

The synthesis of N-substituted 1H-isoindole-1,3-(2H)-diones is described from the reaction of cyclic anhydrides with Schiff bases as suitable replacing substrates instead of the corresponding amines. The Japan Institute of Heterocyclic Chemistry.

Method of inhibiting binding of nerve growth factor to p75 NTR receptor

The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTRcommon neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTRcomprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101and Phe86of nerve growth factor.